+1-888-308-5802     
Industry Categories News Contact Us

Wave-induced motion SUB bioreactor market to observe substantial growth over 2017-2024, U.S. to drive the global industry

Publisher : Fractovia | Published Date : June 2017 | Price : $4500Request Sample

Research organizations have been expending huge investments in the emerging field of biotechnology, which will subsequently fuel Bioreactor Market. The extensive prevalence of chronic ailments has led to an increase in the demand for highly competent medication and therapeutically effective vaccines, which will carve out a lucrative roadmap for bioreactor industry. Major corporations have been implementing strategic mergers & acquisitions to stimulate their business growth and improvise on the product development. For instance, renowned French firm Sartorius Stedim Biotech, a major player in global bioreactor market, recently collaborated with Nova Biomedical, to combine Nova’s cell culture analyzer - BioProfile® FLEX2, with Sartorius’s ambr® multi-parallel bioreactor systems with an aim to generate a dynamic platform that will be designed to sample & analyze numerous cell cultures. This is expected to be carried out as a part of the QbD (quality by design)-led process development approach. Such initiatives will provide an impetus to the growing biotechnology sector, which in turn, will drive bioreactor industry.
 

The bioprocessing market has observed stupendous growth over the last few years, subject to the increasing number of research & development activities that have taken place to develop suitable biopharmaceutical products. In addition, a rise in the adoption of technologies such as tissue engineering and an increase in antibody manufacturing is anticipated to drive bioreactor market.


U.S. Bioreactor Market Share, By Technology, 2016
U.S. Bioreactor Market Share, By Technology, 2016

 

In order to meet the growing demand from the bioprocessing and biopharmaceutical sectors, CMOs (contract manufacturing organizations) have been expanding in terms of capacity and capability. The rise in the number of new compounds making their presence felt in clinical trials will also fuel bioreactor industry, slated to be valued at more than USD 1.9 billion by 2024, with a CAGR estimation of more than 18% over 2017-2024, having held a valuation of more than USD 500 million in 2016.
 

Bioreactor market participants have been striving to develop a wide range of novel products to outdo their rivals. In addition, growth strategies such as M&As, collaborations, and global business expansion will characterize the competitive landscape. For instance, recently, Sartorius acquired kSep Systems, a US-based firm involved in the production of automated centrifugation systems that are utilized to develop vaccines, cell-based therapeutics, and monoclonal antibodies. Such partnerships are likely to provide a positive impetus to global bioreactor market.
 

Speaking along similar lines, bioreactor industry size from monoclonal antibodies was worth more than USD 190 million in 2016 and is expected to grow significantly over the next few years pertaining to its rising application in the treatment of rheumatoid arthritis, chronic gastrointestinal inflammatory disease, asthma, leukemia, transplant rejection, breast cancers, and psoriasis.
 

Monoclonal antibodies accounted for 35% of the bioreactor market share in 2016 and will hold a substantial share by 2024, subject to its use in predictable pharmacokinetics and medical therapeutics.
 

Stem cells find extensive applications in the disease diagnosis and treatment, and are anticipated to witness a CAGR of 18% over 2017-2024. Of late, medical research institutes have been striving to commercialize stem cells so as to develop an alternative line of treatment at crucial stages of an individual’s life. This factor is expected to fuel bioreactor market from stem cells.
 

Speaking along similar lines, R&D organizations accounted for more than USD 250 million in bioreactor industry share in 2016 and are expected to grow significantly over the years ahead. This growth can be credited to the efforts of manufacturers and research scientists to innovate and discover novel products for the biopharmaceutical sector. The United States being a developed economy, is heavily involved in funding R&D institutes for the development of innovative products. On these grounds, U.S. bioreactor market size will surpass USD 600 million by 2024. In addition, the increasing number of biotech firms coupled with collaborations between R&D institutes, academic organizations, and venture capital firms will impel regional bioreactor industry.
 

Bioreactors can be applied to all types of cells, including yeast cells, mammalian cells, and bacterial cells. Yeast cells depict probiotic activity in combination with other probiotic stains, and growing research for manufacturing such probiotic yeasts on an industrial scale will drive bioreactor market from yeast cell, slated to grow at a CAGR of 15% over 2017-2024.
 

Technologically, wave-induced motion SUB accounted for more than 50% of bioreactor industry, subject to its extensive utilization in modern biotech operations. Subject to the benefits of adequate productivity and improvised flexibility, this segment is forecast to grow at a massive rate over the next seven years.
 

Biopharmaceutical manufacturers are another vital end-use segment of bioreactor market, having accounted for more than 30% of the revenue share in 2016. Bioreactor industry from biopharmaceutical manufacturers is expected to grow at a remarkable rate, primarily owing to the rise in the number of biopharma products such as antibody drug conjugates (ADC) and antibodies. In addition, an increase in the number of bioprocessing facilities is forecast to drive the business growth, especially in the developed economies of Europe.
 

Germany held more than 25% of Europe bioreactor market share in 2016, pertaining to the presence of huge biotech firms in the region. Besides, this region is highly developed and possesses the advantage of highly enhanced healthcare facilities. Furthermore, the favorable regulatory landscape for biopharmaceutical product approval and the increased healthcare spending will also propel Germany bioreactor industry over the years to come.
 

Biotechnology, despite tremendous advancements, is still considered a fairly novel field to be experimented with. Nevertheless, the penetration of large-sized corporations across this market is indeed commendable. The rising focus on research & development activities related to the discipline of biotechnology and the advancements in technology will drive bioreactor industry. Top-notch participants of global bioreactor market include Merck Millipore, Thermo Fisher Scientific, Sartorius Stedim Eppendorf Biotech, and GE Healthcare.
 

© 2018 Fractovia. All Rights Reserved